证券代码：000881 证券简称：中广核技 公告编号：2026-007 中广核核技术发展股份有限公司 2026 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开的日期、时间： （1）现场会议时间：2026年2月2日15:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026年2月2日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投 票系统投票的具体时间为2026年2月2日9:15至15:00的任意时间。 2.会议召开方式：本次股东会采取现场投票与网络投票相结合的方式。 3.现场会议召开地点：深圳市福田区深南大道 2002 号中广核大厦北楼 19 层 881 会议室。 4.召集人：公司董事会。 5.主持人：董事长盛国福先生。 6.会议召开的合法、合规性：本次股东会的召开符合《公司法》《上市公司股 东会规则》《深 ...

Core Viewpoint - The company, China General Nuclear Power Technology (CGN), has indicated that its nuclear power cable materials can theoretically be applied in the field of controlled nuclear fusion, although actual suitability depends on the specific application location within fusion devices [1]. Group 1: Product Application - The performance requirements for cables vary significantly across different parts of nuclear fusion systems, with most scenarios being able to meet usage requirements [1]. - For certain extreme environments, polymer cable materials may not meet the necessary performance standards, and mineral insulated cables are typically required in such cases [1]. - Currently, the company does not have any products directly used in the controlled nuclear fusion field [1].

Core Viewpoint - China General Nuclear Power Technology Co., Ltd. (CGN Tech) has indicated that its nuclear power cable materials can theoretically be applied in the field of controlled nuclear fusion, although actual applicability depends on the specific application location within the fusion device [1] Group 1: Product Applicability - The performance requirements for cables vary significantly across different parts of nuclear fusion systems, with most scenarios being able to meet usage requirements [1] - For certain extreme environments, polymer cable materials may not meet the necessary performance standards, and mineral insulated cables are typically required in such cases [1] - Currently, the company does not have any products directly used in the controlled nuclear fusion field [1]

中广核技主要开展电子加速器研发与制造、辐照加工服务、新材料研发与制造、医疗健康业务及测控装备等方面业务。 2025年，中广核技围绕以产品为核心的市场化体系建设，聚焦核技术在医疗和工业领域应用，持续推动产业转型升级。该公司 的加速器及新材料业务均呈现出向好态势。对于业绩亏损，中广核技在公告中解释称主要受对孵化期、产业初期业务持续投入 等因素的影响。 本报讯 （记者李勇）中广核核技术发展股份有限公司（以下简称"中广核技"）1月28日晚间发布了2025年度业绩预告。公 告显示，经初步测算，中广核技预计2025年度归属于上市公司股东的净利润亏损2.4亿—3.4亿元，同比减亏6.12%至33.73%；预 计2025年度归属于上市公司股东的扣除非经常性损益的净利润亏损3.2亿—4.5亿元，同比减亏12.24%至37.60%。 （编辑 张伟） 具体来看，医疗健康业务方面，中广核技2025年继续对质子治疗设备的研发、市场推广及同位素业务加大投入，亏损同比 扩大。此外，中广核技拟对可能发生资产减值的资产计提相应的减值准备，也对利润带来一定影响。 ...

（文章来源：证券日报） 证券日报网讯 1月28日，中广核技发布公告称，公司预计2025年归属于上市公司股东的净利润亏损 24000.00万元至34000.00万元，上年同期亏损36216.76万元。 ...

Core Viewpoint - China General Nuclear Power Technology Co., Ltd. (000881.SZ) expects a loss of 240 million to 340 million yuan in 2025, with a non-recurring loss projected between 320 million to 450 million yuan, indicating ongoing financial challenges as the company invests in market-oriented development and technology applications in healthcare and industrial sectors [1] Financial Performance - The company anticipates a negative net profit for the reporting period due to continued investments in incubation and early-stage business operations [1] - The healthcare segment, particularly in proton therapy equipment and isotope business, has seen an increase in losses compared to the previous year due to heightened R&D and marketing expenditures [1] Asset Management - The company is conducting a comprehensive review and impairment testing of its assets, planning to make provisions for potential asset impairments [1] Non-Recurring Gains and Losses - There has been a decline in non-recurring gains and losses compared to the previous year, primarily due to reduced government subsidies and equity disposal gains recognized in the current period [1]

Core Viewpoint - The company, China General Nuclear Power Technology Co., Ltd. (CGN Tech), is forecasting a significant net loss for the year 2025, with expected losses ranging from 240 million to 340 million yuan for net profit attributable to shareholders, and from 320 million to 450 million yuan for net profit after deducting non-recurring gains and losses [1] Group 1: Financial Performance - The company anticipates a negative net profit for 2025 due to ongoing investments in incubation and early-stage business operations [1] - The medical health business is expected to continue incurring losses, with increased investments in the research and marketing of proton therapy equipment and isotope business leading to a year-on-year expansion of losses [1] - Non-recurring gains and losses are projected to decrease compared to the previous year, primarily due to a reduction in government subsidies and equity disposal gains recognized in the current period [1] Group 2: Business Strategy - The company is focusing on building a market-oriented system centered around its products, emphasizing the application of nuclear technology in the medical and industrial sectors [1] - There is a positive development trend in the accelerator and new materials business, with year-on-year performance improvements [1] - The company is conducting comprehensive asset inspections and impairment tests in accordance with accounting standards, planning to make corresponding impairment provisions for assets that may be subject to impairment [1]

Financial Performance Forecast - The company expects a net loss of between 240 million yuan and 340 million yuan for the year 2025, compared to a net loss of 362.17 million yuan in the same period last year[2]. - The expected net loss attributable to shareholders after deducting non-recurring gains and losses is between 320 million yuan and 450 million yuan, compared to a loss of 512.78 million yuan in the previous year[2]. - Basic earnings per share are projected to be a loss of between 0.2539 yuan and 0.3596 yuan, compared to a loss of 0.3831 yuan per share in the same period last year[2]. - Non-recurring gains and losses have decreased compared to the previous year, primarily due to a reduction in government subsidies and equity disposal gains[5]. - The performance forecast has not been audited by registered accountants, and the final financial data will be disclosed in the 2025 annual report[3][6]. - Investors are advised to be cautious of investment risks as the performance forecast is based on preliminary calculations by the financial department[6]. Business Focus and Development - The company is focusing on the application of nuclear technology in the medical and industrial sectors, with ongoing investments in proton therapy equipment and isotope business, leading to an increased loss in the medical health segment[4]. - The company is accelerating the development of its accelerator and new materials business, which is showing positive growth trends[4]. - The company emphasizes the importance of market-oriented system construction centered around products[4]. Asset Management - The company is undergoing a comprehensive asset inspection and impairment testing, planning to make provisions for potential asset impairments[4].

Group 1 - The core point of the news is that China General Nuclear Power Technology Co., Ltd. (中广核技) experienced a stock price increase of 5.41%, reaching 9.16 CNY per share, with a trading volume of 194 million CNY and a turnover rate of 2.58%, resulting in a total market capitalization of 8.66 billion CNY [1] - The company, established on April 17, 1993, and listed on September 2, 1998, is located in Shenzhen, Guangdong Province, and its main business includes accelerator manufacturing, irradiation processing services, modified polymer materials, and nuclear environmental protection [1] - The revenue composition of the company is as follows: new materials account for 82.38%, other services 8.49%, electronic accelerators and irradiation processing 8.40%, and import-export trade 0.73% [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under Southern Fund ranks among the top shareholders of China General Nuclear Power Technology [2] - The Southern CSI 1000 ETF (512100) reduced its holdings by 43,600 shares in the third quarter, now holding 5.1927 million shares, which represents 0.62% of the circulating shares, with an estimated floating profit of approximately 2.4406 million CNY [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 76.63 billion CNY, achieving a year-to-date return of 8.41% and a one-year return of 43.88% [2]

Key Points - China Metallurgical Group Corporation (China MCC) expects a decline of over 50% in net profit attributable to shareholders in 2025 due to losses in the real estate sector and increased asset impairment provisions [1] - JAC Motors anticipates a net loss of approximately 1.68 billion yuan in 2025, although this represents a reduction in losses compared to the previous year [2] - Northern Rare Earth forecasts a net profit increase of 116.67% to 134.60% in 2025, driven by improved sales and production efficiency in rare earth products [3] - Shenghong Technology projects a net profit increase of 260.35% to 295% in 2025, attributed to the growing demand for AI infrastructure and high-end products [4] - Lanke Technology expects a net profit increase of 52.29% to 66.46% in 2025, benefiting from strong demand in the AI industry [7] - Aiwai Electronics anticipates a net profit increase of 17.70% to 29.47% in 2025, focusing on high-value chip solutions [25] - Longxin General expects a net profit increase of 47.15% to 60.53% in 2025, driven by steady growth in its core motorcycle and general machinery businesses [28] - China One Heavy Industry predicts a net loss of 310 million to 460 million yuan in 2025, although this represents a significant reduction from the previous year's loss [35] - Kunda Technology expects a net loss of 1.2 billion to 1.5 billion yuan in 2025, impacted by industry supply-demand imbalances [34] - Daqing Energy anticipates a net loss of 1 billion to 1.3 billion yuan in 2025, although this reflects a narrowing of losses compared to the previous year [42]